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The aim of this study was to analyze periprocedural and mid-term effect of clopidogrel on platelet function using the VerifyNow
P2Y12 point-of-care assay in patients undergoing TAVI. Platelet reactivity was measured at the beginning of the procedure after
300mgclopidogrelbolusadministrationandduringthefollow-up(at1monthaftertheprocedure)in52patientsundergoingTAVI
usingtheMedtronicCoreValveprosthesis(MedtronicCoreValve).Acutoffvalueof240PRUwasusedtoidentifynonrespondersto
clopidogrel treatment with high residual platelet reactivity (HRPR). Baseline HRPR was identified in 80% of patients and in 72% of
patients during 6-month follow-up. There was no significant difference in the pharmacodynamic effects of clopidogrel on platelet
reactivityfrombaselineto6-monthsfollow-up (297±57vs.275±62;𝑃 = 0.058).Ischemiceventoccurredonlyin3patients(5.8%)
from the study group. In conclusion, majority of patients undergoing TAVI had high residual platelet reactivity after pretreatment
with 300mg of clopidogrel and during the 6-month follow-up at dual antiplatelet treatment. The noneffectiveness of clopidogrel in
the TAVI population raises the question of the routine use of dual antiplatelet treatment in this setting.
1. Introduction
The number of patients with severe aortic stenosis treated
with transcatheter aortic valve implantation (TAVI) is in-
creasing worldwide. This procedure is technically feasible
in the majority of patients at high risk for standard sur-
gical management. However, special attention should be
given to potential periprocedural and short-term follow-
up complications. Risks associated with TAVI differ and
include ischemic (stroke, myocardial infarction) or bleeding
(access site complication, cardiac perforation) complications
at the same time. A loading dose of 300mg of clopidogrel
before TAVI followed by dual antiaggregation therapy with
75mg of clopidogrel for 3–6 months is generally used. This
therapeutic strategy significantly decreases ischemic events
afterpercutaneouscoronaryintervention(PCI)[1].Theeffect
of clopidogrel on platelet reactivity can be tested and high
residual platelet reactivity in approximately 30% of patients
after PCI is associated with increased risk of cardiovascular
death and myocardial infarction during follow-up [2, 3].
However, no data have been reported regarding the effec-
tiveness of clopidogrel in the TAVI setting or its possible
impact on adverse events. Therefore we analyzed the effect of
clopidogrel on platelet function using the VerifyNow P2Y12
point-of-care assay in patients undergoing TAVI.
2. Methods
Wedidtheanalysisinpatientswithsevereaorticstenosiswho
underwent TAVI using the Medtronic CoreValve prosthesis
(MedtronicCoreValve)betweenApril2009andJuly2012.All
interventionswereperformedafterpretreatmentwith300mg
of clopidogrel >12h before the procedure. Dual antiplatelet
therapy with 75mg of clopidogrel and 100mg of acetyl-
salicylic acid was recommended for 6 months followed by
acetylsalicylic acid alone. Platelet reactivity after clopidogrel
treatment was measured by the VerifyNow P2Y12 point-of-
care assay (Accumetrics, San Diego, CA) at baseline (at the2 BioMed Research International
beginning of the procedure) and during the follow-up (at
1 moth after the procedure). The results were expressed as
P2Y12 reaction units (PRU). A cutoff value of 240 PRU was
used to identify non-responders to clopidogrel treatment
with high residual platelet reactivity [2]. Continuous vari-
ables are expressed as mean ± standard deviation; nominal
variablesareexpressedascountandpercentages.Continuous
variables were compared using the unpaired Student’s t-test.
A 𝑃 value of P < 0.05 was considered significant.
3. Results
In total, 70 patients (average age 81 ± 6 years) underwent
TAVI using the Medtronic CoreValve prosthesis. Baseline
VerifyNow testing was successfully performed in 52 patients.
In 8 patients dual antiplatelet treatment was not started
d u et ot h en e e do fc h r o n i co r a la n t i c o a g u l a t i o na n di n1 0
patients errors occurred during testing and thus platelet
reactivity could not be assessed. Clinical characteristics of
patients with baseline platelet reactivity testing are shown in
Table 1. The procedure was successful in 51 patients. There
were six major access site complications caused by major
bleeding that required transfusion and were treated either
surgically (in 3 cases) or by a conservative approach. In one
patient, pericardiocentesis was performed for tamponade.
Ischemic events occurred in three patients, of which one
MI and one stroke occurred during the procedure and one
patient suffered from stroke after discharge. One patient died
during hospitalization for multiple organ failure. Mortality at
6 months was 3.8%. Baseline high residual platelet reactivity
(HRPR) with PRU ≥ 240 was identified in 42 (80%) patients.
Average baseline PRU was 297±57.Co n t r o lV e r i fy N o wt e s t -
ing was performed in 47 patients during 6-month follow-up.
Thirty-four (72%) patients were assigned as nonresponsive
with HRPR. Follow-up average PRU was 275±62.Th e r ew a s
no significant difference in the pharmacodynamic effects of
clopidogrel on platelet reactivity from baseline to 6-months
follow-up (P =0 . 0 5 8 ) .
4. Discussion
Astrategyofclopidogrelpretreatmentfollowedbylong-term
therapy is beneficial in reducing major cardiovascular events
inpatientsundergoingPCI[4].Majorbleedingcomplications
in these patients differ depending on antiaggregant used and
do not exceed the rate of ischemic complications [5, 6].
This is not the case for TAVI where ischemic events are
muchlessfrequentthanbleedingcomplications.Eventhough
cerebral imaging studies have shown a very high incidence
(66%–86%) of new ischemic defects after TAVI, most defects
are clinically silent [7]. The incidence of clinically apparent
stroke after TAVI has an average of about 3% [7]. A German
multicenterregistryincluding697patientstreatedwithTAVI
indicated rates of stroke and myocardial infarction of 2.8%
and 0.3%, respectively [8]. These values were comparable
with FRANCE-2 registry and those reported by Piazza and
by Rod´ es-Cabau [9–11]. On the other hand, major access
site bleeding complication is the most frequent procedural
Table 1: Baseline characteristics of the study population (𝑛=5 2 ).
Age, years (SD) 81 (7)
Female, n (%) 29 (56)
BMI, kg/m
2 (SD) 26.8 (5)
Logistic EuroScore, (SD) 23 (12)
Coronaryarterydisease,n (%) 28 (54)
eGFR < 60mL/min, n (%) 27 (52)
Atrial fibrillation/flutter, n (%) 9 (17)
Previous PCI, n (%) 10 (19)
Previous CABG, n (%) 11 (21)
Previous AVR with bioprosthesis, n (%) 1 (3)
LVEF, % (SD) 51 (12)
LVEF < 40% 17 (32)
AVA index, cm
2/m
2 (SD) 0.42 (0.08)
Femoral approach, n (%) 47 (90)
Subclavian approach, n (%) 5 (10)
complication and is present in 5%–10% of patients under-
going TAVI [7, 9–11]. Thus, special attention should be paid
to reducing these procedural bleeding events. One possible
issue seems to be the strategy of clopidogrel administration.
A ss h o w ni no u ro b s e r v a t i o n ,t h er a t eo fi s c h e m i ce v e n t s
remains acceptable even if the majority of patients has HRPR
a tt h et i m eo fp r o c e d u r ea n df o l l o w - u p .Th i sr a i s e st h e
questionofwhetheritwouldbebeneficialtouseanindividual
approach for clopidogrel administration (e.g., previous PCI,
diffuse coronary artery disease, previous stroke, etc.). Fur-
thermore, our results can also explain findings of two small
randomized study, where the strategy of adding clopidogrel
to aspirin after TAVI was not superior to aspirin alone in
the six-month patients outcomes [12, 13]. Atrial fibrillation is
another important comorbidity that plays role in antithrom-
botic strategy management. Chronic atrial fibrillation occurs
approximately in one-third of patient undergoing TAVI [7].
Several antithrombotic treatment regiments after TAVI are
thus under investigations in ongoing trials [13]b e c a u s et h e
optimal treatment management is still not known.
5. Conclusion
In conclusion, we found that the majority of patients under-
goingTAVIhadhighresidualplateletreactivityafterpretreat-
ment with 300mg of clopidogrel and during the 6-month
follo w-u pa td ualan ti pla telettr ea tmen t.Theno neffectiveness
of clopidogrel in the TAVI population raises the question of
theroutineuseofdualantiplatelettreatmentinthissetting.It
is important to evaluate the antiplatelet treatment strategy in
patients undergoing TAVI in the large randomized study.
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